Hepatitis B Therapy

Novel hepatitis vaccine shows promise

Published in Hepatitis Weekly, January 16th, 2006

CytoGenix, Inc. (CYGX) and Aldevron, LLC announced positive results of a pilot study using CytoGenix synDNA as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response.

DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synthetic DNA vaccine derived from a plasmid provided by Aldevron that produces a Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix synDNA vaccine's activity in a rabbit model using Aldevron's proprietary Genetic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry